Celltrion has a total of 530 patents globally, out of which 218 have been granted. Of these 530 patents, more than 69% patents are active. South Korea is where Celltrion has filed the maximum number of patents, followed by United States of America and European Countries, it has generated an annual revenue of $1.64 billion in the year 2021. Parallelly, South Korea seems to be the main focused R&D centre of Celltrion.
Celltrion was founded in the year 2002 by Jung Jin Seo. The company is a biopharmaceutical company headquartered in Incheon, South Korea. As of July 2022, Celltrion has a market cap of $19.77 Billion.
Do read about some of the most popular patents of Celltrion which have been covered by us in this article and also you can find Celltrion patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Celltrion patent portfolio.
How many patents does the founder and the Chairman of Celltrion have?
The founder and Chairman, Jung Jin Seo, has 0 patents.
How many patents does Celltrion have?
Celltrion has a total of 530 patents globally. These patents belong to 180 unique patent families. Out of 530 patents, 367 patents are active.
How Many Patents did Celltrion File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Celltrion Applications Filed | Celltrion Patents Granted |
| 2011 | 21 | 5 |
| 2012 | 24 | 7 |
| 2013 | 22 | 7 |
| 2014 | 37 | 14 |
| 2015 | 39 | 8 |
| 2016 | 44 | 28 |
| 2017 | 64 | 27 |
| 2018 | 78 | 28 |
| 2019 | 33 | 24 |
| 2020 | 56 | 19 |
| 2021 | 38 | 28 |
| 2022 | 1 | 8 |
How many Celltrion patents are Alive/Dead?
How Many Patents did Celltrion File in Different Countries?
Countries in which Celltrion Filed Patents
| Country | Patents |
| Korea (South) | 187 |
| United States Of America | 38 |
| Europe | 31 |
| Japan | 28 |
| China | 28 |
| India | 14 |
| Hong Kong (S.A.R.) | 14 |
| Canada | 13 |
| Germany | 12 |
| Taiwan | 12 |
| Australia | 12 |
| Spain | 5 |
| Viet Nam | 5 |
| Israel | 5 |
| Mexico | 4 |
| Argentina | 4 |
| Singapore | 4 |
| Brazil | 4 |
| Philippines | 3 |
| New Zealand | 3 |
| Pakistan | 3 |
| Jordan | 3 |
| Costa Rica | 2 |
| Dominican Republic | 2 |
| Cuba | 2 |
| Malaysia | 2 |
| Colombia | 2 |
| Chile | 2 |
| Indonesia | 2 |
| Nicaragua | 2 |
| Tunisia | 2 |
| Panama | 2 |
| Peru | 2 |
| South Africa | 2 |
| Kazakhstan | 1 |
| Uruguay | 1 |
| Austria | 1 |
| Ecuador | 1 |
| Africa | 1 |
| Turkey | 1 |
| Ukraine | 1 |
| Georgia | 1 |
Explore the top-performing drugs that dominate the Pharmaceutical Industry
| Patent Number | Company | Product | Brand | Revenue | Patent Expiry Date |
| US9174975 | Sumitomo Pharma | Lurasidone Hydrochloride | Latuda | $1.75B | Jun-26 |
| US7612199 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7902206 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US8158644 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7371727 | Ironwood Pharma | Linaclotide | Linzess | $1.00B | Mar-25 |
Want to know which drugs are making over $1 Billion annually?
Where are Research Centres of Celltrion Patents Located?
EXCLUSIVE INSIGHTS COMING SOON!
What are Celltrion’s key innovation segments?